Brolucizumab, CAS 1531589-13-5

Product Description: Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment with low picomolar affinity (KD=1.05 pM). Brolucizumab can be used for the research of cancer[1][2].

Applications: Cancer-Kinase/protease

Formula: N/A

References: [1]Szabó E, et, al. Antitumor Activity of DLX1008, an Anti-VEGFA Antibody Fragment with Low Picomolar Affinity, in Human Glioma Models. J Pharmacol Exp Ther. 2018 May;365(2):422-429./[2]Eason AB, et, al. DLX1008 (brolucizumab), a single-chain anti-VEGF-A antibody fragment with low picomolar affinity, leads to tumor involution in an in vivo model of Kaposi Sarcoma. PLoS One. 2020 May 14;15(5):e0233116.

CAS Number: 1531589-13-5

Molecular Weight: N/A

Compound Purity: 97.27

Research Area: Cancer

Solubility: H2O

Target: VEGFR

• Artikelnummer: MEXHY-P9973-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P9973-5
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated